SCHEMBL5158545

SCHEMBL5158545

CCCOC(=O)C(O)(c1ccccc1)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
POLB P06746 1/20 0.68
CHRM2 P08172 6/20 0.66
CHRM1 P11229 6/20 0.66
CHRM3 P20309 6/20 0.66
CHRM4 P08173 3/20 0.66
ALDH1A1 P00352 3/20 0.60
CYP2D6 P10635 3/20 0.58
CHRM5 P08912 2/20 0.58
LMNA P02545 4/20 0.53
GAA P10253 1/20 0.51
KDM4E B2RXH2 2/20 0.50
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
SCN1A P35498 2/20 0.49
SCN2A Q99250 2/20 0.49
SCN3A Q9NY46 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5161453 0.90 MEN1 (0.64) MEN1KMT2APOLBCHRM2CHRM1
SCHEMBL27815600 0.87 MEN1 (0.61) MEN1KMT2APOLBCHRM2CHRM1
SCHEMBL5709937 0.87 MEN1 (0.61) MEN1KMT2APOLBCHRM2CHRM1
SCHEMBL27815598 0.87 MEN1 (0.61) MEN1KMT2APOLBCHRM2CHRM1
SCHEMBL5709848 0.87 MEN1 (0.61) MEN1KMT2APOLBCHRM2CHRM1
SCHEMBL2488938 0.86 CHRM2 (0.56) MEN1KMT2APOLBCHRM2CHRM1
SCHEMBL2763579 0.85 POLB (0.62) MEN1KMT2APOLBCHRM2CHRM1
SCHEMBL5810680 0.84 LMNA (0.51) MEN1KMT2APOLBCHRM2CHRM1
SCHEMBL15310066 0.84 MEN1 (0.51) MEN1KMT2APOLBCHRM2CHRM1
SCHEMBL29925238 0.84 CHRM3 (0.60) MEN1KMT2APOLBCHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006119283-A2 ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE YU RUEY J (US) 2006-11-09 WO claimed
US-20060251597-A1 ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE YU RUEY J 2006-11-09 US claimed
WO-2025132660-A1 METHOD FOR TREATING HUMAN PERSPIRATION, AND ASSOCIATED COMPOSITION L'OREAL (FR) 2025-06-26 WO disclosed
US-20250009621-A1 ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER L'OREAL (FR) 2025-01-09 US disclosed
WO-2025006991-A1 ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER L'OREAL (FR) 2025-01-02 WO disclosed
EP-1275645-B1 LABELED COMPOUNDS FOR MEASURING THE FUNCTION OF THE MUSCARINIC ACETYLCHOLINE NERVOUS SYSTEM HAMAMATSU PHOTONICS KK (JP) 2007-02-28 EP disclosed
WO-2006119283-A2 ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE YU RUEY J (US) 2006-11-09 WO disclosed
US-20060251597-A1 ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE YU RUEY J 2006-11-09 US disclosed
EP-0831767-B1 ALPHA HYDROXYACID ESTERS FOR SKIN AGING YU RUEY J (US) 2004-09-22 EP disclosed
US-6649142-B2 Labeled compounds for measuring the function of the muscarinic acetylcholine nervous system HAMAMATSU PHOTONICS K.K. (JP) 2003-11-18 US disclosed
US-20030113261-A1 Labeled compounds for measuring the function of the muscarinic acetylcholine nervous system HAMAMATSU PHOTONICS K.K. (JP) 2003-06-19 US disclosed
EP-1275645-A1 LABELED COMPOUNDS FOR MEASURING THE FUNCTION OF THE MUSCARINIC ACETYLCHOLINE NERVOUS SYSTEM HAMAMATSU PHOTONICS K. K. (JP) 2003-01-15 EP disclosed
EP-0831767-A4 ALPHA HYDROXYACID ESTERS FOR SKIN AGING YU RUEY J (US) 2000-05-17 EP disclosed
EP-0831767-A1 ALPHA HYDROXYACID ESTERS FOR SKIN AGING Yu, Ruey J., Dr. (US) 1998-04-01 EP disclosed
US-5686489-A TOPICALLY APPLIED TO INDUCE GLYCOSAMINOGLYCAN, PROTEOGLYCAN, COLLAGEN AND ELASTIN BIOSYNTHESIS; WRINKLE RESISTANCE TRISTRATA TECHNOLOGY, INC. (US) 1997-11-11 US disclosed
WO-1996040047-A1 ALPHA HYDROXYACID ESTERS FOR SKIN AGING YU RUEY J (US) 1996-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030113261-A1 Labeled compounds for measuring the function of the muscarinic acetylcholine nervous system CHRM3, CHRM5, CHRM2 MEN1 666/4885KMT2A 2694/4885POLB 4141/4885
US-20250009621-A1 ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER EBP, ADH1A, ADH1C MEN1 2253/4885KMT2A 2260/4885POLB 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.